The Year in Biotech and What’s Ahead in 2022

FromThe Bio Report

Start listening View podcast show

The Year in Biotech and What’s Ahead in 2022

FromThe Bio Report

ratings:

Length:

25 minutes

Released:

Dec 30, 2021

Format:

Podcast episode

Description

As 2021 fades into the history books, it will be remembered as one with exuberant IPOs, punishing aftermarkets, and a lingering pandemic that once again is turning the annual JPMorgan Healthcare Conference into a virtual event. We continue our annual tradition of sitting down with STAT Senior Writer Adam Feuerstein to discuss the year that was in biotech, the best and worst CEOs of 2021, and what’s ahead in the new year.

Released:

Dec 30, 2021

Format:

Podcast episode

Titles in the series (100)

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Skip carousel

Remembering Industry Pioneer Ron Cape by The Bio Report
27 min listen
Telemedicine Grows, but Reimbursement Remains an Obstacle: While many may think of telemedicine as an example of digital health technologies that will reshape the future landscape of medicine, a new survey from the law firm Foley & Lardner shows it is very much part of healthcare’s here and now. We spoke to ... by The Bio Report
22 min listen
How New Funding Models Are Accelerating Drug Development: News last month of the Cystic Fibrosis Foundation’s $3.3 billion sale of royalty rights to Kalydeco and other Vertex Pharmaceuticals drugs it helped fund served as a bold statement to the growing prominence and power of venture philanthropy. We spok... by The Bio Report
18 min listen
How One Foundation is Getting the Biggest Bang for Its R&D Bucks: As pressure on government and corporate research budgets grow, organizations like the Multiple Myeloma Research Foundation are playing an increasingly critical role in advancing and accelerating drug development. The foundation’s efforts, including i... by The Bio Report
28 min listen
Epirus Sees Opportunities for Biosimilars Outside U.S.: The regulatory pathway for biosimilars is still a work in progress at the U.S. Food and Drug Administration, but around the world the industry is growing as regulators have resolved issues that remain obstacles in the United States. We spoke to Amit ... by The Bio Report
18 min listen
Reengineering Drug Discovery and Development: Drugmakers have employed new technologies to reduce the cost and time and it takes develop drugs and produce therapies that more precisely target the underlying biology driving diseases. Boston-based Berg Pharma is using artificial intelligence with ... by The Bio Report
21 min listen
A Look at the Year That Was in Biotech: The year 2014 was one for the record books for the biotech industry. In part one of a two-part podcast, we take a look back at the year that was with Adam Feuerstein, senior columnist for TheStreet.com. Feuerstein discusses the growing controversy ov... by The Bio Report
15 min listen
Moving from Chronic Therapies to Cures: The rapidly growing area of regenerative medicine is promising to replace chronic therapies with cures. As the biotechnology industry gathers in San Francisco for a big week of meetings, the Alliance for Regenerative Medicine is readying to deliver i... by The Bio Report
22 min listen
International Collaboration Seeks to Drive Breakthroughs in Progressive MS: There has been dramatic progress in the understanding and treatment of relapsing remitting multiple sclerosis, a debilitating neurodegenerative disorder. But progressive MS, a more advanced form of the disease, has remained elusive. Now, a novel coll... by The Bio Report
24 min listen
The Lean Startup Takes Hold in the Life Sciences: The National Science Foundation and the National Institutes of Health, concerned about seeing the science they fund commercialized, have embraced the Lean Startup method as a way to improve the odds of success for new companies. Steve Blank, whose wo... by The Bio Report
23 min listen
The Power of IBM’s Watson Is Coming to an App Near You: IBM’s Watson Group recently announced an investment in Pathway Genomics, part of a $100 million initiative by the computing giant to spur innovation in entrepreneurial companies that seek to leverage its cognitive computing platform Watson. Pathway G... by The Bio Report
18 min listen
Using Human Biology to Improve R&D: One problem with drug discovery and development is that answers about the way substances act in the human body are often not apparent early in the process. Though human cell assays have been used, they have their limitations. BioSeek’s BioMap technol... by The Bio Report
28 min listen
Reinventing Tech Transfer: Universities are moving away from a passive approach to technology transfer to engage with industry in new partnerships, put a greater emphasis on translational research, and nurturing technologies so they can give rise to new products and companies.... by The Bio Report
21 min listen
Will Increased FDA Regulation of Diagnostics Speed or Slow Development of Personalized Medicine: The U.S. Food and Drug Administration is moving to expand its regulatory domain by adding oversight of certain diagnostics it does not regulate today. The agency says thousands of these test are used daily to guide treatment decisions and diagnose di... by The Bio Report
27 min listen
Brittany Maynard and the Debate over the Right to Die: Brittany Maynard, a 29-year-old woman with terminal brain cancer who chose to end her own life with a lethal dose of medication, sparked a renewed discussion of so-called death with dignity laws. Maynard had become visible on social and traditional m... by The Bio Report
23 min listen
ALS Fight Carries Muller from Patient to Biotech CEO: Bernard Muller was a successful businessman in the maritime and oil industry, but when he was diagnosed with the neurodegenerative disease ALS in 2010, he turned his entrepreneurial skills toward developing new therapies to treat the disease. Muller ... by The Bio Report
18 min listen
Why Privacy Concerns May Limit Big Data’s Payoff: Two-thirds of Americans say they are willing to anonymously share their health information with researchers, but only about 1 in 5 is willing to provide their purchase history or social media activity, according to a recent Truven Health Analytics-NP... by The Bio Report
14 min listen
How One Company Is Reinventing Drug Development: Tomasz Sablinski believes the drug development process is broken and has sought to reinvent it. His company, Transparency Life Sciences, relies on crowdsourcing to design its clinical trials, makes all of its data public, and employs digital technolo... by The Bio Report
34 min listen
The Forces Bringing Disruptive Change to Healthcare: Scientific breakthroughs, innovations in technology, and the changing use of data are among the forces that are driving disruptive changes to healthcare. A new report from the IMS Institute for Healthcare Informatics highlights a number of these deve... by The Bio Report
21 min listen
The Year in Biotech So Far and What’s Ahead: The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP... by The Bio Report
22 min listen
Measuring the Value of Incubators and Accelerators: Incubators and accelerators have been proliferating in California, but little has been done to track their activities and analyze their performance. The California Business Incubation Alliance recently released a study of the performance of incubator... by The Bio Report
23 min listen
Enlisting Monoclonal Antibodies to Combat Bacterial Resistance: There’s growing global concern about threat from antibiotic resistant pathogens. That’s leading to new interest in looking beyond traditional antibiotics to monoclonal antibodies to address the problem. We spoke to Ken Stover, senior director of infe... by The Bio Report
21 min listen
Examining the State of Sleep: Sleep researchers and clinicians will be gathering in Seattle June 6 - 10 for SLEEP 2015, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. It is the largest gathering of sleep medicine physicians, sleep and ci... by The Bio Report
24 min listen
What’s Driving the Booming Market for Orphan Drugs: The market for Orphan drugs is growing at more than twice the rate of other prescription medicines In 2013, a record 260 therapeutics won orphan designations in the United States alone as science, policy, and pricing are fueling the trend for drugmak... by The Bio Report
18 min listen
Why Interoperability Is Much More than a Technology Problem: A new government report finds that healthcare providers in the United States are increasing their adoption of health information technology, but their willingness to do so is tied to the incentives available. What’s more, the government is implementi... by The Bio Report
26 min listen
Thinking Narrowly About Antibiotics: With the mapping of the human microbiome, a new understanding is emerging of the complex relationship between the microorganisms that live in the human gut, skin, and elsewhere on the body, and the role they play both in disease and in maintaining he... by The Bio Report
24 min listen
CrowdMed Enlists the Wisdom of Crowds to Solve Medical Mysteries: For many patients with rare and difficult to diagnose conditions, it can take many years and many doctors to find a correct answer. CrowdMed is trying to offering an alternative to patients by allowing them to tap the wisdom of crowds and letting med... by The Bio Report
19 min listen
Should Investors Temper Their Enthusiasm for CAR-T Therapies: CAR-T cell immunotherapies seek to harness the body’s immune system to fight tumor cells. The promise of this new class of therapies has ignited investor’s imaginations, but a new report from EP Vantage argues that the enthusiasm that has driven valu... by The Bio Report
24 min listen
What to Do About the United States’ Declining Investment in R&D: Investment in biomedical research in the United States is declining at a time when other countries have been increasing their spending. While this is raising concerns about the threats this poses to the nation’s economic competitiveness, a new study ... by The Bio Report
16 min listen
Home-Brew Morphine, Dual Use Technology, and the Biologist’s Repsonsibilities: A recent article in Nature Chemical Biology that shows it is possible to convert sugar into morphine with genetically engineered yeast has sparked public attention over the potential illicit use of the technology and the need for regulation. The work... by The Bio Report
20 min listen

More Episodes from The Bio Report

Skip carousel

How Solving a Problem with Genetic Medicines May Solve Another with Infectious Diseases: One of the challenges facing genetic medicines is delivering payloads across the human cell membrane and inside cells both effectively and with high tolerability. Aegis Life is capitalizing on its parent Entos Pharmaceuticals’ nucleic acid delivery p... by The Bio Report
25 min listen
Boosting the Power of Dendritic Cancer Vaccines: The idea of developing cancer vaccines that harness dendritic cells is not new, but Diakonos Oncology thinks it’s been able to solve the lack of efficacy that has plagued this approach. The company combines its vaccines with RNA and proteins from a p... by The Bio Report
19 min listen
Overcoming Resistance in Cancer with Chemistry: Kinase inhibitors have given rise to an era of precision medicine for the treatment of cancer, but the ability of cancer cells to mutate enables tumors to develop resistance to existing therapies. Nuvalent is developing therapies that both target the... by The Bio Report
30 min listen
Teaching an Old Drug a New Trick to Prevent Lyme Disease: Each year, an estimated 400,000 people in the United States will be diagnosed with Lyme disease, a billion-dollar healthcare problem caused by a bacterial infection that is transmitted through the bite of a tick. The condition can cause joint pain an... by The Bio Report
20 min listen
A New Class of Cell Therapies to Target Solid Tumors: In February, the U.S. Food and Drug Administration approved the first tumor-infiltrating lymphocyte, or TIL therapy, for solid tumors. The approval was hailed as a milestone that points the path forward for a new class of cell therapies for solid tum... by The Bio Report
33 min listen
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies: Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight cancer. The company’s technology platform is seeking to change the immunotherapy landscape with new treatments that are bette... by The Bio Report
35 min listen
A Company Born from a Father Who Wore His Heart on His Sleeve: Jeremiah Robison’s daughter Sofia was born with cerebral palsy, a congenital movement disorder. Watching her physicians use body monitors to measure her gait, and later apply functional electrical stimulation as physical therapy, gave him an idea to ... by The Bio Report
32 min listen
Using AI to Improve Burn Care: Physicians treating people with burns typically incorrectly assess the depth of burn wounds in about 25 to 30 percent of cases. That, in part, is due to a lack of diagnostic tools to assess the severity of a burn and to determine the best approach to... by The Bio Report
24 min listen
A Home for Biotech in the City that Never Sleeps: New York City is not the first place that comes to mind when thinking of biotech clusters, but the Big Apple has been a growing center of biomedical innovation with its mix of academic research hospitals, finance, and growing number of biopharmaceuti... by The Bio Report
33 min listen
Biopharma R&D Growing Stronger: Funding levels, drug launches, and R&D success rates all grew in 2023, according to a new report from the IQVIA Institute for Human Data Science. Global funding of biopharmaceutical research and development increased to $72 billion, up from $61 b... by The Bio Report
31 min listen
The Benefits of Having a Multitude of Cins: In January 2023, AstraZeneca agreed to acquire CinCor Pharma, the CinRx cardio-renal disease therapy subsidiary, for $1.3 billion. The deal included a potential additional $500 million milestone payment. The price represented a 121 percent premium to... by The Bio Report
33 min listen
Making ADCs Smarter and Safer with a Simple Twist of Fate: Antibody-drug conjugates can deliver chemotherapy directly to tumors but more than 95 percent of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Mythic Therapeutics FateControl technology improves the uptake of... by The Bio Report
24 min listen
Targeting a Natural Repair System to Restore Brain Health: The HGF/MET neurotrophic system plays a critical role in the maintenance and repair of connections in the brain. Enhanced signaling along this pathway has the potential to reduce inflammation, slow neurodegeneration, and provide neuroprotection. Athi... by The Bio Report
19 min listen
Programing Cells in a Predictable and Scalable Way: The advent of induced pluripotent stem cells, cells that can be coaxed into becoming virtually any type of cell within the body, promised to usher in a new era of regenerative medicine and improved drug discovery. In practice, though, the ability to ... by The Bio Report
32 min listen
Why DNA May Be the Data Storage Medium of the Future: Some 100 trillion gigabytes of data are created and consumed each year, an amount that is expected to double by 2025. The demand for data storage carries the need for significant physical space and power requirements in the form of digital data cente... by The Bio Report
32 min listen
Scouring Genetic Variation within Our Cells for Drug Targets: People tend to think of each person having their own unique genome. Quotient Therapeutics is taking an approach to drug discovery based on the reality that from cell to cell within a given individual, there can be trillions of divergent genomes. Chan... by The Bio Report
26 min listen
Correcting Gene Dysregulation to Treat Diseases: Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression... by The Bio Report
45 min listen
Using Technology to Regain Abilities after Spinal Cord Injury: The effects of spinal cord injury extend beyond the loss of mobility. They can include a toll on mental health, a feeling of exclusion, and a general decline in the quality of life as a result of being able to stand and interact eye-to-eye with other... by The Bio Report
25 min listen
Why Drug Developers Have a Growing Interest in Targeting Mitochondria: Mitochondria are often referred to as the “powerhouses” of the cell, but as scientists gain a greater understanding of these essential organelles, they are coming to discover they play a more expansive role in health and disease. The Foundation for t... by The Bio Report
39 min listen
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates: Sandbox AQ, the Alphabet spin-out backed with $500 million in investment, in June 2023 unveiled it AQBioSim division. The division is working to bring SandoxAQ’s AI and quantum-inspired computing to develop new treatments for intractable medical cond... by The Bio Report
32 min listen
Targeting a Multitude of CIN in Cancer Cells: It’s long been understood that chromosomal instability (CIN) is a characteristic of cancer cells, but it also represents a key difference between cancer cells and healthy cells that can be exploited. Volastra is developing medicines for a wide range ... by The Bio Report
21 min listen
The Year in Biotech and What’s Ahead in 2024: Though the year began with a banking crisis and has been marked with layoffs and restructurings, we have managed to avoid a feared recession. It’s been a big year for new drug approvals, M&A activity has been brisk, and biotech stocks have rallie... by The Bio Report
33 min listen
Transforming Healthcare with Data: Vik Bajaj has long lived at the intersection of physical sciences, engineering, data science, and the life sciences—first as an academic working to improve diagnostic imaging at Stanford University and later as a chief scientific officer at GRAIL and... by The Bio Report
51 min listen
Realizing the Promise of IL-2 Therapies with AI: Interleukin-2 therapies have been seen as promising ways to treat solid tumors, but they have proven challenging because of the ability of IL-2 to both activate and suppress the immune system. Their effectiveness has been limited because of potential... by The Bio Report
23 min listen
Unlocking Real-World Data to Improve Outcomes: Real-world data promises to provide insights that lead to better therapies, change how we treat diseases, and improve outcomes for patients. One of the limits of realizing benefits from all of the health information we are swimming in is the lack of ... by The Bio Report
40 min listen
A Silicon Valley Entrepreneur Investing at the Intersection of Tech and Biotech: Artificial intelligence promises to reshape the healthcare landscape and deliver new insights into the molecular drivers of health and wellness, provide rapid diagnoses of patients, and discover and design therapies that extend beyond human imaginati... by The Bio Report
25 min listen
A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery: Though many drug developers are harnessing AI to create novel chemical compounds, Iambic Therapeutic’s generative AI is leveraging quantum mechanics to get to better drugs. It says its physics-informed machine learning approach has yielded promising ... by The Bio Report
24 min listen
Detecting Alzheimer’s Disease Early through a Blood Test: One of the challenges with treating Alzheimer’s disease is diagnosing patients early enough in the course of its progression to have a meaningful impact with treatments. Sunbird Bio said it can accurately detect and differentiate specific proteins th... by The Bio Report
25 min listen
Addressing Supply-Chain Challenges Underlying Drug Shortages with Synthetic Biology: About 40 percent of all drugs in the Western world are derived from plants. But challenges with producing a reliable supply inherent with materials derived from agricultural processes can lead to drug shortages as climate events, pests, and plant dis... by The Bio Report
28 min listen
Building Better and More Affordable Vaccines: The COVID 19 pandemic provided a painful reminder of the global need to protect people against the threat of existing and emerging infectious diseases. Emergex Vaccines is developing fully synthetic vaccines that provide advantages over live attenuat... by The Bio Report
42 min listen

Related podcast episodes

Skip carousel

The Year in Biotech and What to Watch in 2019: As the year draws to a close, we continue what’s become an annual tradition and look back on the year in biotech and ahead to the J.P. Morgan Healthcare Conference and beyond with Adam Feuerstein, senior biotech writer for STAT News. Adam tries to ma... by The Bio Report
26 min listen
The Year in Biotech and What’s Ahead in 2024: Though the year began with a banking crisis and has been marked with layoffs and restructurings, we have managed to avoid a feared recession. It’s been a big year for new drug approvals, M&A activity has been brisk, and biotech stocks have rallie... by The Bio Report
33 min listen
The Year in Biotech and What’s Ahead in 2021: The raging pandemic defined 2020, but it was a big year for biotech as the industry saw soaring stocks, record investment, and an impressive number of new drug approvals despite disruptions from COVID-19. We continue our annual tradition of sitting d... by The Bio Report
31 min listen
The Year in Biotech and What’s Ahead in 2023: It was a difficult year for biotechs with drops in the major biotech indices, fewer new drug approvals, and more than 125 companies announcing layoffs. But there were also triumphs to celebrate. We continue our annual tradition of ending the old year... by The Bio Report
33 min listen
Biotech in 2016 and the Year Ahead with TheStreet’s Adam Feuerstein: With 2016 drawing to a close and the biotech industry gearing up for the annual JPMorgan Healthcare Conference in San Francisco, we continued our holiday tradition of checking in with Adam Feuerstein, senior columnist for TheStreet. We spoke to Feuer... by The Bio Report
21 min listen
53: What will health care look like in 2021?: Host Rachel Woods sits down with Advisory Board's Christopher Kerns and Yulan Egan to discuss what the health care industry might look like in 2021 and what we can expect from different stakeholders. by Radio Advisory
26 min listen
Taking a look back at 2020 in Spartanburg: It's a year when the word "unprecedented" became commonplace. Beginning with a February tornado that cut a swath through the heart of our city and followed shortly by the COVID-19 global pandemic that still rages as the year comes to a close, 2020 is... by Spartanburg City News
56 min listen
The Big Stories Of 2023 and What To Expect In 2024: In this podcast I walk through the big business and HR stories of 2023 and what they tell us for the year ahead. 2024 looks like a year with a strong economy, continued labor shortages, with employees continuing to take charge. And as you expect, AI will change everything. And there's one big story that defines everything, but you'll have to listen to the podcast to hear it. Join me as we look ahead and stay tuned for our detailed 2024 Predictions report coming in January. by The Josh Bersin Company
24 min listen
2020: Maybe it Wasn’t All Bad w/ Liz Hosman: With 2020 finally in the rearview mirror, many of us are reflecting back on the challenges we faced over the past year. It certainly was a difficult year for a lot of people, but maybe it wasn’t all bad. Hopefully we all learned some things, and emerged from 2020 stronger, a little more empathetic, a little wise, and a whole lot more flexible. If 2020 showed us anything, it’s that we’re all far more resilient than we ever thought. On this episode of CFO Weekly, our guest is Liz Hosman. Liz is the VP of Finance at March Communications, a technology PR agency dedicated to B2B and consumer tech brands across all sectors, but primarily those in the enterprise tech, AI, and wellness and health tech sectors. Our conversation centered on The challenges faced in 2020 How those challenges altered the landscape of her organization How she and her team plan to keep the positive changes going into 2021 and beyond. Why Yoga is playing a key role in by CFO Weekly
21 min listen
2020 Year in Review: Breakthroughs and Discoveries in Psychological Science: What happens when the APS media relations director chats with the APS senior science writer? A fun discussion on 2020's most interesting research, that's what! Many of the major news stories of 2020 were closely tied to understanding human behavior, incl... by Under the Cortex
22 min listen
How America's Biggest Food Companies Felt the Pinch of the Pandemic: Despite all of the pantry stocking and comfort food eating that took place in 2020, sales for the food and beverage industry’s top 100 manufacturers came in at only 1.7% over 2019’s sales figures. In this episode, Food Processing's Dave Fusaro and Pan D... by Food Processing’s Food For Thought Podcast
24 min listen
Leadership in a Time of Change: Caring for Yourself, Your Patients, and Your Team: The year 2020 has proven to be a year like no other. From a global pandemic to concerns surrounding social injustice, we have been forced to slow down and conduct a self-assessment on how best to take care of ourselves, our families, and our patient... by ASHPOfficial
20 min listen
100. Olympic Breakdancing, Election Fever and Collective Effervescence – WGSN’s 2024 preview by Create Tomorrow, The WGSN Podcast
21 min listen
#24 What the 2020 Election Will Mean for the Baking Industry: Robb MacKie, Lee Sanders and Kelly Knowles, ABA by Bake to the Future
38 min listen
2020 Influenza Vaccine & the COVID-19 Pandemic: An Ambulatory Care Perspective: With the combination of the 2020 influenza season and the COVID-19 pandemic, both patients and pharmacy professionals need to be vigilant about protecting themselves. In this podcast, Drs. Martin Bishop and Lauren Cimino discuss the important role ... by ASHPOfficial
8 min listen
2nd-Half Preview, Summer Reading for Investors: Rising more than 14% the S&P 500 had its 2nd-best start to the year this century! But meme stocks and inflation also became headline stories for investors. Emily Flippen and Jason Moser look back at the 1st half of 2021 and share why Procore’s... by Motley Fool Money
39 min listen
Blake's Top 5 Customer Experience Predictions For 2021: Every year, I make predictions for what’s to come in the world of customer experience. After doing this for seven years, I’ve gotten pretty good at predicting trends that really do end up influencing businesses and customers. But in 2020, no one... by The Modern Customer Podcast
22 min listen
Ep. 2: The State of Houston's Startup and Funding Scene with Josh Pherigo by Bayou Business Download
10 min listen
Prophecies For 2019 A Stan 01-10-19 - Audio: What can we expect to happen in 2019? Are we heading for a much more turbulent year ahead, as some expect? What should we look for as signposts for the future? Stan gives an overview of what we are likely to see in 2019, and how this relates to prophec… by The Prophecy Club - All Broadcasts
30 min listen
2019 Stan 01-08-19 - Audio: What can we expect to happen in 2019? Are we heading for a much more turbulent year ahead, as some expect? What should we look for as signposts for the future? Stan gives an overview of what we are likely to see in 2019, and how this relates to pro… by The Prophecy Club - All Broadcasts
30 min listen
2019 Will Be Like Nothing You Have Ever Seen Before Stan 01-18-19 - Audio: What can we expect to happen in 2019? Are we heading for a much more turbulent year ahead, as some expect? What should we look for as signposts for the future? Stan gives an overview of what we are likely to see in 2019, and how this relates to prophec… by The Prophecy Club - All Broadcasts
30 min listen
2020 Year in Review (Cutting Room Floor #086): 2020: you were a motherf*cker. For real, this year has been an all-timer of a year. It's challenged our perception of what a year even IS. And it's come from all sides: personal, professional, global. 2020 will always be the year of COVID-19 . . . but... by Film School
54 min listen
How human capital and corporate culture have evolved due to COVID‐19: We laid our cards on the table and predicted five trends that would reshape ESG investing in January 2020. But then fate played its COVID‐19 wildcard. In this episode, we take a look at how much things have changed, how much they haven't and how human capital risks may emerge in a post‐pandemic world. by ESG now
24 min listen
Andrew Sheets: Challenges to the 2022 Story Emerge by Thoughts on the Market
3 min listen
From Colorado to Washington: Editor-in-Chief Alan Weil discusses his past, healthcare’s future: We turn the tables in this episode and ask Health Affairs Editor-in-Chief Alan Weil about his educational background, what it means to be the editor for the leading health policy journal, how empirical research has changed since the COVID-19 pandemic, his by A Health Podyssey
26 min listen
Mergers & Acquisitions in 2021 and Beyond w/ Steven Nutt: It’s no secret that 2020 has been hard for businesses. This is particularly true in the mergers and acquisitions space. According to one study, mergers and acquisitions were down 57% in 2020 from where they were in 2019. While the year started off strong, by March, M&A had all but come to a screeching halt. What does the future hold for M&A? What can we expect moving into 2021 and beyond? On this episode of CFO Weekly, we were pleased to sit down with Steven Nutt. Steven is the Chief Financial Officer at Community National Bank & Trust of Texas, as well as a repeat guest. Steven joined us in episode four of CFO Weekly, and on this current episode, we talked all about The M&A outlook for 2021 How buyers can properly value targets How sellers can position themselves to command a top price. For more interviews from the CFO Weekly podcast, check us out on Apple or Spotify or your favorite podcast player! Presented by CFO Weekly
35 min listen
Biotech Is Back with Allan Shaw by Business Of Biotech
51 min listen
Special edition: The world after coronavirus: Where's the upside? by GZERO World with Ian Bremmer
36 min listen
7investing Team Podcast: Our Reckless Predictions for 2022 by The 7investing Podcast
19 min listen
I Don’t Care If It’s Fake News, I Believe It: While the past several decades can rightly be called the “information age,” the rise of social media platforms makes is seem like the past few years could be considered the misinformation age. The viral nature of alternative facts, rumors, and planned di... by Under the Cortex
16 min listen

Discover this podcast and so much more

The Year in Biotech and What’s Ahead in 2022

The Year in Biotech and What’s Ahead in 2022

Description

Titles in the series (100)

More Episodes from The Bio Report

Related podcast episodes